Nyxoah (NYXH) EPS (Weighted Average and Diluted) (2021 - 2026)
Nyxoah (NYXH) recorded quarterly EPS (Weighted Average and Diluted) of $44.0 million in Q1 2026, down 99.56% quarter-over-quarter from $9.9 billion in Q4 2025, and up 17.66% on a YoY basis from $37.4 million in Q1 2025.
Nyxoah (NYXH) EPS (Weighted Average and Diluted) (2021 - 2026) Analysis & Trends
Nyxoah's EPS (Weighted Average and Diluted) history runs 6 years deep, the most recent figure standing at $44.0 million for Q1 2026.
- In Q1 2026, EPS (Weighted Average and Diluted) rose 17.66% year-over-year to $44.0 million; the TTM figure through Mar 2026 stood at $44.0 million (up 17.66% YoY), while the FY2025 annual figure was -$2.75, down 42.35% from the prior year.
- EPS (Weighted Average and Diluted) was $44.0 million for Q1 2026 at Nyxoah, down from $9.9 billion in the prior quarter.
- In the past five years, EPS (Weighted Average and Diluted) ranged from a high of $26.0 billion in Q1 2023 to a low of -$9.5 million in Q4 2024.
- Historically, EPS (Weighted Average and Diluted) has averaged $2.1 billion across 5 years, with a median of $14.2 million in 2023.
- The sharpest annual moves came in 2022 and 2023: EPS (Weighted Average and Diluted) plunged 194.0% in 2022, then jumped 128177.05% in 2023.
- A 5-year view of EPS (Weighted Average and Diluted) shows it stood at $11.0 million in 2022, then sank by 164.05% to -$7.1 million in 2023, then sank by 34.46% to -$9.5 million in 2024, then jumped by 105020.5% to $9.9 billion in 2025, then tumbled by 99.56% to $44.0 million in 2026.
- The last three EPS (Weighted Average and Diluted) figures came in at $44.0 million (Q1 2026), $9.9 billion (Q4 2025), and $13.3 million (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EPS (Weighted Avg. Diluted) (Qtr) |
|---|---|---|---|---|---|
| 1 | Intuitive Surgical | 148.09 Bn | 143.69 Bn | 1.83 Bn | 2.28 |
| 2 | Becton Dickinson | 41.00 Bn | 39.99 Bn | 2.15 Bn | -1.11 |
| 3 | Medline | 30.38 Bn | 36.22 Bn | 1.84 Bn | 0.16 |
| 4 | Resmed | 28.22 Bn | 26.56 Bn | 890.98 Mn | 2.74 |
| 5 | West Pharmaceutical Services | 23.72 Bn | 23.19 Bn | 296.40 Mn | 1.92 |
| 6 | Solventum | 13.33 Bn | 13.33 Bn | 1.10 Bn | 0.07 |
| 7 | Cooper Companies | 13.12 Bn | 12.99 Bn | 735.40 Mn | -0.40 |
| 8 | Align Technology | 12.86 Bn | 11.80 Bn | 736.59 Mn | 1.57 |
| 9 | Baxter International | 10.51 Bn | 8.47 Bn | 891.00 Mn | -0.03 |
| 10 | Nyxoah | 0.69 | 0.69 | 4.26 Mn | 44.05 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 44.05 Mn |
| Dec 31, 2025 | 9.95 Bn |
| Sep 30, 2025 | 13.28 Mn |
| Jun 30, 2025 | 17.73 Mn |
| Mar 31, 2025 | 37.43 Mn |
| Dec 31, 2024 | -9.48 Mn |
| Sep 30, 2024 | 12.83 Mn |
| Jun 30, 2024 | 15.67 Mn |
| Mar 31, 2024 | 28.69 Mn |
| Dec 31, 2023 | -7.05 Mn |
| Sep 30, 2023 | -6.54 Mn |
| Jun 30, 2023 | 14.16 Mn |
| Mar 31, 2023 | 25.95 Bn |
| Dec 31, 2022 | 11.01 Mn |
| Sep 30, 2022 | -8.98 Mn |
| Jun 30, 2022 | 11,041.94 |
| Mar 31, 2022 | 26.17 Mn |
| Dec 31, 2021 | 5.45 Mn |
| Sep 30, 2021 | 9.55 Mn |
| Jun 30, 2021 | 12,173.68 |